Immunovant(IMVT)
DURHAM, NCBiotechnology
Focus: Immunovant is a public biotechnology company focused on monoclonal antibodies for autoimmune diseases across neurology, immunology, and endocrinology. The company is in clinical-stage development with a robust pipeline of 19 active trials.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
5-1 this month
Stable — net -1 jobs in 30d
3 added, 4 removed. Backfill posture.
Should You Work at Immunovant?
AI assessmentImmunovant is a clinical-stage focused play suitable for scientists and clinicians seeking high clinical impact and portfolio breadth, but carries significant execution and financing risk typical of pre-revenue biotechs.
Why Work Here
- Strong pipeline momentum with 5 Phase 3 programs and 14 Phase 2 programs, offering multiple clinical catalysts through 2026–2027
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
5 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
IMVT-1402
Graves' DiseaseClinical Trials (1)
NCT07286006A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
Phase 2Help build intelligence for Immunovant
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.